<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ychou, Marc</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of Adjuvant Treatment with 5-FU/Leucovorin plus Irinotecan for Colorectal Cancer Metastases to the Liver</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-10</style></pages><abstract><style  face="normal" font="default" size="100%">Adjuvant 5-FU-based chemotherapy regimens have improved survival for patients with colorectal cancer metastases to the liver compared with surgery alone. The findings of an international, randomized phase 3 trial [NCT00143403] indicate that the addition of irinotecan to 5-FU/leucovorin did not lead to further improvement in this setting.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>